LENSAR to Participate in the BTIG 4th Annual Ophthalmology Day
26 Novembre 2024 - 2:00PM
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global
medical technology company focused on advanced robotic laser
solutions for the treatment of cataracts, today announced Nick
Curtis, Chief Executive Officer, will participate in a fireside
chat at the BTIG 4th Annual Ophthalmology Day on Monday, December
2, 2024 at 2 p.m. ET. Additionally, LENSAR management will host
1-on-1 meetings with institutional investors.
BTIG hosted events are intended for prospective and existing
BTIG clients only. To listen to the live event, please contact your
BTIG representative.
About LENSAR
LENSAR is a commercial-stage medical device company focused
on designing, developing, and marketing advanced systems for the
treatment of cataracts and the management of astigmatism as an
integral aspect of the procedure. LENSAR has developed
its ALLY Robotic Cataract Laser System™ as a compact, highly
ergonomic system utilizing an extremely fast dual-modality laser
and integrating AI into proprietary imaging and software. ALLY is
designed to transform premium cataract surgery by utilizing
LENSAR’s advanced robotic technologies with the ability to perform
the entire procedure in a sterile operating room or in-office
surgical suite, delivering operational efficiencies and reducing
overhead. ALLY includes LENSAR’s proprietary
Streamline ® software technology, which is designed to
guide surgeons to achieve better outcomes.
Contacts: |
|
Lee Roth / Cameron Radinovic |
Thomas R. Staab, II, CFO |
|
Burns McClellan for LENSAR |
ir.contact@lensar.com |
|
lroth@burnsmc.com / cradinovic@burnsmc.com |
LENSAR (NASDAQ:LNSR)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
LENSAR (NASDAQ:LNSR)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025